Modeling Pharmacodynamic Response to the Poly(ADP- Ribose) Polymerase Inhibitor ABT-888 in Human (original) (raw)
Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
Larry Rubinstein
PLoS ONE, 2011
View PDFchevron_right
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
Larry Rubinstein
Journal of Clinical Oncology, 2009
View PDFchevron_right
Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts
Larry Rubinstein
Clinical Cancer Research, 2008
View PDFchevron_right
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
luis rodriguez
Clinical Cancer Research, 2007
View PDFchevron_right
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective
Shahneen Sandhu
European Journal of Cancer, 2010
View PDFchevron_right
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Nicola Curtin
Molecular Cancer Therapeutics, 2007
View PDFchevron_right
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers
Nicola Curtin
Biochemical Journal, 2011
View PDFchevron_right
Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Miguel Fuertes
Recent Patents on Anti-Cancer Drug Discovery, 2006
View PDFchevron_right
Predictive biomarkers for cancer therapy with PARP inhibitors
Murat Saparbaev
Oncogene, 2013
View PDFchevron_right
Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
Lesley Robson, Nicola Curtin
Clinical Cancer Research, 2008
View PDFchevron_right
A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy
Annamalai Arunachalam
Future medicinal chemistry, 2017
View PDFchevron_right
Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Shahneen Sandhu
CA: A Cancer Journal for Clinicians, 2011
View PDFchevron_right
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis
Francesco Schettini
View PDFchevron_right
Opportunities for repurposing of poly(ADP-ribose) polymerase (PARP) inhibitors for the therapy of non-oncological diseases
Nicola Curtin
British journal of pharmacology, 2017
View PDFchevron_right
PARP expression and activity 1 Poly ( ADP-ribose ) polymerase-1 ( PARP-1 ) pharmacogene tics , activity and expression analysis in cancer patients and healthy volunteers
Nicola Curtin
2012
View PDFchevron_right
Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality
Alessandra Cesano
Molecular medicine (Cambridge, Mass.), 2011
View PDFchevron_right
Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials
Nicola Curtin
Cancer Chemotherapy and Pharmacology, 2010
View PDFchevron_right
Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
George Pappas-Gogos
Annals of Translational Medicine
View PDFchevron_right
Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?
Majid Ali
Clinical Cancer Research, 2009
View PDFchevron_right
Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
Malina Patel
Critical Reviews in Eukaryotic Gene Expression, 2014
View PDFchevron_right
An improved nonisotopic test to screen a large series of new inhibitor molecules of poly(ADP-ribose) polymerase activity for therapeutic applications
Patrice Decker
Clinical cancer research : an official journal of the American Association for Cancer Research, 1999
View PDFchevron_right
PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies
Robert Mach
Radiology, 2016
View PDFchevron_right
Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma
Marie Boyd
Annals of Surgical Oncology, 2010
View PDFchevron_right